Agios Pharmaceuticals, Inc.

NasdaqGS AGIO

Agios Pharmaceuticals, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 1.00 B

Agios Pharmaceuticals, Inc. Cash and Short-Term Investments is USD 1.00 B for the quarter ending September 30, 2024, a 15.17% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Agios Pharmaceuticals, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 872.39 M, a 19.89% change year over year.
Agios Pharmaceuticals, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 727.68 M, a -42.52% change year over year.
Agios Pharmaceuticals, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 1.27 B, a 109.08% change year over year.
Agios Pharmaceuticals, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 605.54 M, a 34.00% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: AGIO

Agios Pharmaceuticals, Inc.

CEO	Mr. Brian M. Goff M.B.A.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street
Employees	383
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years